key: cord-344765-agt60ksx
authors: Bhogal, R.H.; Patel, P.H.; Doran, S.L.F.; Zar, S.; Pollok, J.M.; Jiao, L.R.; Allum, W.H.; Chaudry, M.A.; Kumar, S.
title: Approach to upper GastroIntestinal cancer surgery during the COVID-19 pandemic – Experience from a UK cancer centre
date: 2020-05-30
journal: Eur J Surg Oncol
DOI: 10.1016/j.ejso.2020.05.022
sha: 
doc_id: 344765
cord_uid: agt60ksx

nan

. This plan was expanded and the strategy refined when our centre became the designated Specialist 'Cancer Hub' for West London. This clinical model was established to allow time-critical oncology surgery to be delivered to all patients from across our cancer network. All elective surgical cancer patients were requested to self-isolate for 14 days before surgery, complete a COVID-19 symptom questionnaire and undergo mandatory pre-operative COVID-19 swab testing and CT thorax immediately prior to surgery. Every patient case was reviewed in our Specialist Upper GI Multidisciplinary (sMDT) meeting and treatment plans were personalised taking account of patient comorbidities, tumour biology and availability of alternative oncological treatments. Our decision-making for the surgical prioritisation also incorporated individual patient performance status/perioperative risk and potential resource implications. All patients were requested to complete a COVID-risk consent form. Our strategy focused on clinical cases considered priorities 1 (i.e., Emergency/Urgent) & 2 (i.e., surgery that can be deferred up to 4 weeks). It was compulsory for theatre teams to wear full Personal Protective Equipment including surgical masks or filtering face piece respirators. Patients presenting with bleeding gastric tumours or gastric outlet obstruction not amenable to endoscopic/interventional radiological control were considered for surgical intervention. Oesophageal cancer emergencies (bleeding/perforation) were deemed for endoscopic/radiological intervention during the pandemic period given the poor prognosis associated with this presentation and the need for prolonged Level 3 care when surgery is undertaken. All T1a & T1b oesophageal/gastric tumours were evaluated by a specialist Upper GI gastroenterologist and considered for endoscopic resection. Oesophageal or gastric cancer patients on an intention-to-cure pathway, who had completed their neoadjuvant chemotherapy and had undergone postchemotherapy assessment of resectability/treatment response in the sMDT, were considered for resection. Patients with stable Gastrointestinal Stromal Tumours (GIST) continued on imatinib treatment or surgery was deferred until all priority 2 cases had been completed. Our institution undertook a safety-first approach and minimally invasive surgery was not feasible during the early phase of the pandemic -we agreed to postpone staging laparoscopy for newly diagnosed patients until completion of neoadjuvant treatment. With limited endoscopy resources, patients presenting with painless jaundice, radiological evidence of both pancreatic and biliary duct obstruction and associated pancreatic mass were prioritised for resection. Patients presenting with a pancreatic mass and gastric outlet obstruction not amenable to endoscopic stenting were also considered for surgery. Our rationalised Upper GI endoscopy service was utilised to investigate patients with single duct obstruction or isolated pancreatic masses. In the absence of effective neoadjuvant chemotherapy regimens, patients with primary liver cancer (Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC)) were considered for hepatic resection. We considered liver resection of ≤3 Couinaud segments or right/left hepatectomy appropriate during this period. Extended liver resections and Associating Liver Partition with Portal Vein Ligation (ALPPS) were not undertaken due to the known higher patient morbidity and mortality. Patients requiring extended resection were considered for alternative oncological treatments. In patients with colorectal liver metastasis, where multiple atypical/non-anatomical liver resections were required and future liver remnant volume was satisfactory, patients were considered for hepatectomy. Extensive bilobar liver metastasis were not considered for surgical intervention. Pancreatic/liver cysts and neuroendocrine tumours were deferred in line with our priority guidance. This framework has allowed us to triage Upper GI cancer patients in a resource-limited environment and safely deliver the maximum number of potentially curative operations during the COVID-19 pandemic.

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

COVID-19 infection in patients following hepato-pancreatico-biliary intervention: An early experience